Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program Written by Petra Hegmann on 14th May 2020. Posted in Client News. Previous Next